Trial Condition(s):
Hepatocellular carcinoma
Use of Sorafenib and/or Regorafenib in liver cancer (hepatocellular carcinoma) subsequent to another systemic first-line treatment (SORAGO-HCC)
Bayer Identifier:
20215
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Trial Purpose
Researchers already did trials that showed Sorafenib and Regorafenib worked for patients with hepatocellular carcinoma (most common liver tumor type).
In this trial, they want to learn more about the same patient group in which Sorafenib or Regorafenib is given after other drugs. Patients participating in this study will be observed until 12 months after the last patient has been enrolled to collect data on how safe the drugs are and how well they are working when used as second line or beyond treatment.
Inclusion Criteria
- Diagnosis of hepatocellular cancer in stage BCLC-B or BCLC-C - Decision to initiate treatment with Nexavar (sorafenib) and/or Stivarga (regorafenib) as 2nd-line or beyond treatment was made as per investigator’s routine treatment practice. Stivarga (regorafenib) must be used according to its indication, i.e. after prior progression under Nexavar (sorafenib) treatment.
Exclusion Criteria
- Patients concurrently participating in an investigational program for the treatment of HCC with interventions outside of routine clinical practice. - Stivarga (regorafenib) treatment without prior therapy with Nexavar (sorafenib). NOTE: Nexavar (sorafenib) treatment could have been given as treatment for HCC outside of this non-interventional study. In this case Stivarga (regorafenib) would NOT constitute the second-line therapy after direct pretreatment with Nexavar (sorafenib) but e.g. 3rd-line treatment directly after a different drug. - Contra-indications according to the local marketing authorization.
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | |
|---|---|
Locations Many Locations Many Locations, Germany | Contact Us: E-mail: [email protected] Phone: (+)1-888-84 22937 |
Trial Design
Use of Sorafenib and/or Regorafenib in hepatocellular carcinoma (HCC) subsequent to another systemic first-line treatment
Trial Type:
Observational
Intervention Type:
Drug
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
1
Primary Outcome
- Identification of current treatment patterns by means of individual treatment lines in the systemic HCC therapy with regards to Nexavar and Stivarga, i.e. when both drugs are used in ≥ 2nd-line under current practice conditionsTimeframe: Up to 24 months
Secondary Outcome
- Overall Survival (OS) from start of Nexavar or Stivarga therapy and from start of first systemic therapyTimeframe: Up to 36 months
- Progression free survival (PFS)Timeframe: Up to 36 months
- Time to progression (TTP)Timeframe: Up to 36 months
- Duration of Nexavar or Stivarga treatmentTimeframe: Up to 36 months
- Tumor response to treatmentEvaluated by the investigator according to the categories “complete response”, “partial response”, “stable disease”, “progressive disease by clinical judgment”, “progressive disease measurement proven”, “unknown” and “not applicable”, and will be analyzed providing absolute and relative frequencies of the tumor status categories.Timeframe: Up to 36 months
- Incidence of treatment-emergent adverse events (TEAE)Timeframe: Up to 36 months
Additional Information
Copyright © Bayer
Powered by
